特利加压素与肝肾综合征-急性肾损伤:从过去到未来的综述
肝肾综合征是失代偿期肝硬化患者特有的罕见且高致残性肾损伤,由门静脉高压导致功能性肾损伤,可通过恢复有效循环血量和肾灌注逆转。特利加压素作为一种作用于内脏循环的V1a受体激动剂,多年来在美国以外用于治疗肝肾综合征,近期获FDA批准后引发新关注。本文综述了肝肾综合征的病理生理学与诊断标准、特利加压素的临床应用及替代疗法,并指出了未来研究方向。
要点
- 肝肾综合征是失代偿期肝硬化患者的功能性肾损伤,恢复有效循环血量可逆转。
- 特利加压素是V1a受体激动剂,作用于内脏循环,近期获FDA批准用于肝肾综合征。
- 肝移植是唯一确定性治愈手段,血管收缩剂联合白蛋白是支持治疗基石。
核心结论
- 特利加压素获FDA批准后,需要新的处方群体将其纳入临床实践,未来需进一步研究肝肾综合征和肝硬化肾损伤。
研究设计与样本
- 本文为综述,回顾了肝肾综合征的病理生理学和诊断标准、特利加压素的临床使用及替代疗法,并识别未来研究领域。
主要发现
- 肝肾综合征是门静脉高压的生理性后果,导致功能性肾损伤,可通过恢复有效循环血量和肾灌注逆转。
- 肝移植是唯一确定性治愈手段,血管收缩剂联合静脉白蛋白是支持治疗基石。
- 特利加压素是一种作用于内脏循环的V1a受体激动剂,多年来在美国以外用于治疗肝肾综合征。
临床怎么用
- 临床医生可将特利加压素纳入肝肾综合征的临床实践,作为血管收缩剂联合白蛋白支持治疗的一部分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatorenal syndrome (HRS) is a rare and highly morbid form of kidney injury unique to patients with decompensated cirrhosis. HRS is a physiologic consequence of portal hypertension, leading to a functional kidney injury that can be reversed by restoring effective circulating volume and renal perfusion. While liver transplantation is the only definitive "cure" for HRS, medical management with vasoconstrictors and i.v. albumin is a cornerstone of supportive care. Terlipressin, a V1a receptor agonist that acts on the splanchnic circulation, has been used for many years outside the United States for the treatment of HRS. However, its recent Food and Drug Administration approval has generated new interest in this population, as a new base of prescribers now work to incorporate the drug into clinical practice. In this article, we review HRS pathophysiology and diagnostic criteria, the clinical use of terlipressin and alternative therapies, and identify areas of future research in the space of HRS and kidney injury in cirrhosis.
引用
- Allegretti AS, Patidar KR, Ma AT, et al. From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury. Hepatology. 2024. PMID: 38353565. doi:10.1097/HEP.0000000000000790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。